94 related articles for article (PubMed ID: 26898077)
1. FOXP1 Expression in Normal and Neoplastic Erythroid and Myeloid Cells.
Lovrić E; Pavlov KH; Korać P; Dominis M
Coll Antropol; 2015 Sep; 39(3):755-9. PubMed ID: 26898077
[TBL] [Abstract][Full Text] [Related]
2. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
4. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
8. The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma.
Brown P; Marafioti T; Kusec R; Banham AH
J Mol Histol; 2005 May; 36(4):249-56. PubMed ID: 16200457
[TBL] [Abstract][Full Text] [Related]
9. TGFα expression in myeloid malignancies.
Kavanagh S; Mirzai B; Fuller K; Erber WN
J Clin Pathol; 2016 Jun; 69(6):543-6. PubMed ID: 26984929
[TBL] [Abstract][Full Text] [Related]
10. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms.
Trifa AP; Popp RA; Cucuianu A; Coadă CA; Urian LG; Militaru MS; Bănescu C; Dima D; Farcaş MF; Crişan TO; Petrov L; Gug C; Pop IV
Leuk Lymphoma; 2012 Dec; 53(12):2496-7. PubMed ID: 22339435
[No Abstract] [Full Text] [Related]
11. Beta-thromboglobulin content in megakaryocytes of patients with myeloproliferative diseases.
Grossi A; Vannucchi AM; Rafanelli D; Filimberti E; Rossi Ferrini P
Thromb Res; 1986 Aug; 43(3):367-74. PubMed ID: 2426823
[No Abstract] [Full Text] [Related]
12. FOXP1 and BCL2 show similar immunoenzymatic pattern in bone marrow trephines of chronic lymphocytic leukemia patients.
Korać P; Vintar MG; Ajduković R; Kardum Paro MM; Jaksić B; Dominis M
Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):500-4. PubMed ID: 19417623
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
14. α-Hemoglobin-stabilizing Protein: An Effective Marker for Erythroid Precursors in Bone Marrow Biopsy Specimens.
Yu H; Pinkus JL; Pinkus GS
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):51-6. PubMed ID: 25611244
[TBL] [Abstract][Full Text] [Related]
15. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
17. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
Silva M; Richard C; Benito A; Sanz C; Olalla I; Fernández-Luna JL
N Engl J Med; 1998 Feb; 338(9):564-71. PubMed ID: 9475763
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
19. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.
Ohler L; Geissler K; Hinterberger W
Wien Klin Wochenschr; 2003 Aug; 115(13-14):537-46. PubMed ID: 13677271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
